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Background: Post-traumatic stress disorder (PTSD) is a chronic anxiety disorder that is often difﬁcult to
treat. Patients suffering from PTSD often fail to respond to antidepressants and may have a high inci-
dence of positive symptoms of psychosis, though antipsychotic medications have been minimally studied
in this population. The aim of this study was to assess the impact of the atypical antipsychotic ziprasi-
done (Geodon) on PTSD symptom clusters, as well as comorbid major depressive disorder. To our
knowledge, this is the ﬁrst completed randomized controlled trial investigating the potential efﬁcacy and
tolerability of ziprasidone in patients with chronic PTSD.
Methods: We conducted a 9-week prospective, randomized, double-blind, placebo-controlled trial of
ziprasidone in 30 patients diagnosed with PTSD and comorbid depression. After screening and
randomization, patients completed nine weekly study visits at which treatment safety and efﬁcacy were
evaluated. Primary measures of efﬁcacy included total and subscale scores from the Clinician-
Administered PTSD Scale (CAPS), while the Hamilton Rating Scale for Depression (HAM-D), Hamilton
Anxiety Scale (HAM-A), Clinical Global Impression (CGI), and Treatment Outcome PTSD Scale (TOP-8)
were implemented as secondary efﬁcacy measures.
Results: We observed no signiﬁcant effect of treatment on reduction of PTSD or depression symptoms
from pre- to post-treatment.
Conclusions: Our ﬁndings suggest that ziprasidone treatment may not signiﬁcantly improve symptoms of
PTSD or comorbid depression, though further study is needed.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Post-traumatic stress disorder (PTSD) is a chronic anxiety dis-
order with a high lifetime prevalence of 7.8% (10.4% for women and
5% for men) [1] that is often difﬁcult to treat. PTSD is characterized
by symptoms in three clusters: intrusive, avoidant, and hyper-
arousal. The intrusive symptom cluster, which includes ﬂashbacks,
nightmares, intrusive thoughts, and physiological and psychologi-
cal arousal upon reminders of the trauma, is considered unique to
PTSD and not seen in any other psychiatric condition. Additionally,fairs, Nebraska-Western Iowa
, NE 68105, USA.
maswamy).
access article under the CC BY-NCthe intrusive symptom cluster has proved difﬁcult to treat suc-
cessfully with conventional psychotherapeutic and pharmaco-
therapeutic approaches.
Presently, two medications, sertraline (Zoloft) [2,3] and parox-
etine (Paxil) [4,5] have U.S. Food and Drug Administration (FDA)
approval for the indication of treating PTSD. Unfortunately, many
patients with PTSD are unresponsive, have only moderate or mar-
ginal responses, or have troubling side effects to ﬁrst-line selective
serotonin reuptake inhibitor (SSRI) treatment. In addition, current
SSRI trials have found that more than 50% of patients still have
signiﬁcant residual symptoms, which can be highly incapacitating.
Recent studies suggest that patients suffering from combat-
associated PTSD may have a high incidence of positive symptoms
of psychosis [6e9], and these patients especially frequently fail to-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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minimally studied; however, some research suggests their useful-
ness in PTSD patients with marked paranoia, anger, and/or ﬂash-
backs [10e13]. That hypothesis is also supported by biological study
ﬁndings of abnormal dopamine function [14] and reports of
elevated peripheral (urinary and plasma) dopamine levels in PTSD
patients [15].
Ziprasidone (Geodon) is a new-generation (atypical) antipsy-
chotic with a benign side effect proﬁle (e.g., extrapyramidal side
effects comparable to placebo). To date, there is little evidence
concerning the efﬁcacy and tolerability of ziprasidone in PTSD,
though one report [16] suggests that ziprasidone can be effective
and well tolerated in this population. There is one reported ran-
domized placebo-controlled trial of ziprasidone as add-on to SSRI
treatment for PTSD [17], though the trial was terminated early,
making it difﬁcult to draw conclusions regarding the efﬁcacy of
ziprasidone.
We conducted a 9-week, prospective double-blind trial of
ziprasidone speciﬁcally designed to assess the impact of ziprasi-
done on PTSD symptom clusters. Also, as PTSD has an extensive
comorbidity withmajor depressive disorder [18], the clinical trial of
ziprasidone in PTSD was intended to help delineate its potential
antidepressant spectrum of efﬁcacy and anxiolytic proﬁle. To our
knowledge, this is the ﬁrst completed randomized controlled trial
investigating the potential efﬁcacy and tolerability of ziprasidone in
patients with chronic PTSD.
2. Materials and methods
2.1. Participants
Participants were recruited from the outpatient mental health
clinic at Creighton University and community referrals. The diag-
nosis of PTSD was made during a comprehensive screening evalu-
ation for PTSD program entry. The study protocol was approved by
the Creighton University Institutional Review Board. Informed
consent of all participants was obtained after the nature of the
procedures had been fully explained and prior to study
participation.
Patients had tomeet the following inclusion criteria: (1) male or
female patients aged 19e64 years meeting DSM-IV criteria for
PTSD; (2) competent to provide informed consent; (3) able to
attendweekly clinic appointments; (4) if female, using an approved
contraceptive if of childbearing potential. Patients were excluded
from the study if they had any of the following: (1) history of prior
treatment with ziprasidone; (2) medical condition that may pre-
vent safe administration of ziprasidone, such as clinically signiﬁ-
cant/severe hepatic, cardiac, kidney, or pulmonary disease and
seizure disorders, with the exception of childhood seizure disor-
ders; (3) primary major psychotic disorder (i.e., schizophrenia,
schizoaffective disorder, or bipolar disorder); (4) suicidal or homi-
cidal ideation or other clinically signiﬁcant dangerousness; (5)
change in psychotropic medication within 90 days of study entry.
2.2. Study procedures
During the screening evaluation, patients received a compre-
hensive psychiatric evaluation, as well as a physical examination
and urine drug screen. Laboratory tests (clinical chemistry and
hematology) were also performed if indicated by the patient's
medical history. Patients who met eligibility criteria were ran-
domized either to ziprasidone group or placebo group. Patients
completed a total of nine weekly study visits and were provided
with a pager number to contact the study coordinator 24 h per day
for adverse event reporting. The beginning dose of ziprasidone was20 mg administered twice daily. The dose was increased in 20 mg
increments twice daily, up to 80 mg twice daily. Concomitant an-
tidepressant and other psychotropic (including antipsychotic)
medications were permitted if they were maintained at a constant
dose for at least 3 months before baseline visit.
2.3. Assessment of effectiveness
The primary outcome measure was the Clinician-Administered
PTSD Scale (CAPS), which was administered at study visits 1, 7,
and 9. The CAPS is a clinician-administered scale used to assess the
core PTSD symptoms of the DSM-IV. Higher scores on the CAPS
indicate greater severity of PTSD symptoms. The primary efﬁcacy
variable was the change from visit 1 (baseline) to visit 9 (endpoint)
in the global scores on the CAPS. Clinically signiﬁcant improvement
on the CAPS score was deﬁned a priori as at least a 50% decrease
from baseline to endpoint. We also examined the number of pa-
tients showing at least a 30% decrease on the CAPS over the course
of the study.
The Hamilton Anxiety Scale (HAM-A), Hamilton Rating Scale for
Depression (HAM-D), Clinical Global Impression (CGI), and Treat-
ment Outcome PTSD Scale (TOP-8) were administered as secondary
outcome measures at each study visit. Higher scores on the HAM-A
reﬂect greater severity of anxiety symptoms, while higher scores on
the HAM-D reﬂect greater severity of depression symptoms. The
CGI is a clinician-administered scale with two items used to rate
illness severity (CGI-S) and global improvement from baseline
(CGI-I). Higher scores on the CGI-S reﬂect greater illness severity,
while lower scores on the CGI-I indicate greater improvement.
Higher scores on the TOP-8 reﬂect greater severity of PTSD symp-
toms. Utilizing the secondary measures, the data also helped to
determine whether the improvement in PTSD symptoms was
entirely a function of treating depression and/or anxiety symptoms,
or whether there were additional effects on PTSD. The change from
baseline to endpoint was measured. At the end of the acute phase,
patients who elected to continue in treatment in the research clinic
were administered open-label ziprasidone at individual doses for
an additional 12 weeks.
2.4. Assessment of safety and tolerability
Adverse events and vital signs were evaluated at each visit. Each
patient had a pager number to contact the study coordinator 24 h
per day for adverse event reporting.
2.5. Statistical analyses
Categorical data, including demographics, were assessed with
descriptive statistics. Treatment group was compared over time
with repeated measures, mixed-effects models. The outcome
measures of interest were total CAPS score, and CAPS B (Intrusion),
C (Avoidance), and D (Hyperarousal) subscale scores. The repeated
measures model included treatment, visit (as a categorical vari-
able), and treatment*visit interaction ﬁxed effects. An unstructured
covariance matrix was used to ﬁt the within-patient repeated
measures. Pairwise comparison p-values from the mixed models
were adjusted with Tukey's method. Fisher's exact test was also
used to compare treatment response between groups.
Paired t-tests were used to compare the change on secondary
efﬁcacy measures between the treatment groups from baseline to
visit 9. For the primary outcome variable a p-value less than 0.05 is
considered to be statistically signiﬁcant, while other statistical
comparisons are exploratory. SAS software version 9.1 (SAS Insti-
tute, Cary, NC) was used for the analyses.
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3.1. Patient characteristics
Fifty two patients were recruited for the study, including 15who
screen failed and seven who were lost to follow up, resulting in a
total of 30 randomized in the study. Patients randomized to the
ziprasidone group (n ¼ 15) included 3 male and 12 female patients
(Mean age ¼ 39.5, SD ¼ 14.8), while the placebo group (n ¼ 15)
included 1 male and 14 female patients (Mean age ¼ 38.3,
SD¼ 8.4). The two groups did not differ signiﬁcantly with regard to
age (t (28) ¼ 0.26, P > 0.7) or sex distribution (Fisher's exact test,
P > 0.5).3.2. Efﬁcacy of ziprasidone
Results for CAPS total score, and CAPS B (Intrusion), C (Avoid-
ance), and D (Hyperarousal) subscale scores at visit 1 (baseline),
visit 7, and visit 9 (endpoint) are summarized in Table 1. The pla-
cebo group had patient numbers of n ¼ 15 at visit 1, n ¼ 9 at visit 7,
and n¼ 13 at visit 9. The ziprasidone group had patient numbers of
n ¼ 15 at visit 1, n ¼ 10 at visit 7, and n ¼ 12 at visit 9. The two
groups did not differ signiﬁcantly on any of the CAPS scores at
baseline. When analyzing the CAPS total score as the outcome
variable, the treatment*visit interaction was not signiﬁcant (F
(2,28) ¼ 0.49, P ¼ 0.62), indicating that the effect of treatment did
not differ by visit, and therefore, the interaction was excluded from
the model. The main effects model showed a signiﬁcant visit effect
(F (2,28) ¼ 10.36, P ¼ 0.0004), but not a treatment effect (F
(1,28) ¼ 0.18, P ¼ 0.67). On average, CAPS total score decreased by
18.2 (SE ¼ 4.3) from visit 1 to visit 7 (t (28) ¼ 4.01, adjusted
P ¼ 0.0012) and by 25.2 (SE ¼ 5.6) from visit 1 to visit 9 (t
(28) ¼ 4.49, adjusted P ¼ 0.0003). After adjusting for multiple
comparisons the difference between visit 7 and 9 was not statis-
tically signiﬁcant (t (28)¼ 2.03, adjusted P¼ 0.12). CAPS total scores
across visits for each group are illustrated in Figs A1 and A2.
For CAPS B, C, and D subscale scores, the treatment*visit inter-
action was not signiﬁcant (Ps > 0.5), indicating that the effect of
treatment did not differ by visit, and therefore, the interaction was
excluded from the model. For CAPS B, the main effects model
showed a signiﬁcant visit effect (F (2,28) ¼ 6.12, P ¼ 0.0062), with
scores decreasing by 4.3 (SE ¼ 1.5) from visit 1 to visit 7 (t
(28) ¼ 2.83, adjusted P ¼ 0.022) and by 7.2 (SE ¼ 2.1) from visit 1 to
visit 9 (t (28) ¼ 3.5, adjusted P ¼ 0.0044). After adjusting for mul-
tiple comparisons the difference between visit 7 and 9 was notTable 1
CAPS scores by treatment group and visit.
Outcome measure Visit Ziprasidone
Mean (SE)
Placebo
Mean (SE)
Adjusted
P-value
CAPS Total score 1
7
9
79.9 (4.6)
62.1 (7.8)
51.7 (8.4)
75.4 (4.6)
56.7 (7.9)
53.1 (8.3)
0.98
0.99
1.0
CAPS B (Intrusion) 1
7
9
21.0 (2.2)
16.7 (2.4)
14.0 (2.9)
21.0 (2.2)
16.8 (2.4)
13.7 (2.9)
1.0
1.0
1.0
CAPS C (Avoidance) 1
7
9
33.9 (1.7)
26.8 (3.5)
22.5 (3.8)
31.0 (1.7)
23.3 (3.6)
22.8 (3.8)
0.85
0.98
1.0
CAPS D (Hyperarousal) 1
7
9
25.1 (1.7)
18.8 (2.7)
15.6 (2.4)
23.4 (1.7)
17.9 (2.7)
16.8 (2.4)
0.98
1.0
1.0
CAPS: Clinician Administered PTSD Scale.
Note: CAPS scores at visit 7 were unavailable for 11 patients (5 in ziprasidone group
and 6 in placebo group). CAPS scores at visit 9 were unavailable for ﬁve patients (3 in
ziprasidone group and 2 in placebo group).statistically signiﬁcant (t (28) ¼ 2.45, adjusted P ¼ 0.053). For CAPS
C, the main effects model showed a signiﬁcant visit effect (F
(2,28) ¼ 8.22, P ¼ 0.0016), with scores decreasing by 7.4 (SE ¼ 2.1)
from visit 1 to visit 7 (t (28) ¼ 3.52, adjusted P ¼ 0.0041) and by 9.7
(SE ¼ 2.4) from visit 1 to visit 9 (t (28) ¼ 3.97, adjusted P ¼ 0.0013).
After adjusting for multiple comparisons the difference between
visit 7 and 9 was not statistically signiﬁcant (t (28) ¼ 1.43, adjusted
P ¼ 0.34). For CAPS D, the main effects model showed a signiﬁcant
visit effect (F (2,28) ¼ 11.36, P ¼ 0.0002), with scores decreasing by
5.9 (SE ¼ 1.7) from visit 1 to visit 7 (t (28) ¼ 3.49, adjusted
P¼ 0.0045) and by 8.0 (SE¼ 1.7) fromvisit 1 to visit 9 (t (28)¼ 4.76,
adjusted P ¼ 0.0002). After adjusting for multiple comparisons the
difference between visit 7 and 9 was not statistically signiﬁcant (t
(28) ¼ 1.65, adjusted P ¼ 0.24). No signiﬁcant main effects of
treatment were observed (Ps > 0.3).3.3. Response rate
The response rate was deﬁned as a greater than 50% decrease in
total CAPS score fromvisit 1 (baseline) to visit 9 (endpoint). We also
looked at the rate of response deﬁned as a 30% decrease. Based on
the 50% decrease criterion, response rate was 25% in the active
treatment group and 23% in the placebo group. Using the 30%
decrease criterion, response rate was 50% in the active treatment
group and 54% in the placebo group. Response rates were not
signiﬁcantly different between the groups for total CAPS score or
any of the subscales (as shown in Table 2).3.4. Secondary efﬁcacy
Results for secondary efﬁcacy measures are summarized in
Table 3. Scores on secondary efﬁcacy measures were unavailable at
visit 9 for four patients (2 in ziprasidone group and 2 in placebo
group). Baseline CGI-S was unavailable for one patient in the
ziprasidone group, and visit 2 CGI-I was unavailable for one patient
in the placebo group. There was no signiﬁcant difference between
treatment groups at baseline on any of the measures. Change from
baseline to visit 9 was also not signiﬁcantly different between
groups on the HAM-A (t (24) ¼ 1.12, P > 0.2), HAM-D (t
(24) ¼ 1.28, P > 0.2) CGI-S (t (23) ¼ 0.64, P > 0.5), CGI-I (t
(23) ¼ 0.86, P > 0.4), or TOP-8 (t (24) ¼ 0.85, P > 0.4).Table 2
Response rate comparison by group.
Outcome measure Response rate Ziprasidone
N (%)
Placebo
N (%)
P-value
CAPS total score <50% decrease
>¼50% decrease
9 (75%)
3 (25%)
10 (77%)
3 (23%)
1.0
<30% decrease
>¼30% decrease
6 (50%)
6 (50%)
6 (46%)
7 (54%)
1.0
CAPS B (Intrusion) <50% decrease
>¼50% decrease
8 (67%)
4 (33%)
8 (62%)
5 (38%)
1.0
<30% decrease
>¼30% decrease
6 (50%)
6 (50%)
6 (46%)
7 (54%)
1.0
CAPS C (Avoidance) <50% decrease
>¼50% decrease
8 (67%)
4 (33%)
10 (77%)
3 (23%)
0.67
<30% decrease
>¼30% decrease
6 (50%)
6 (50%)
7 (54%)
6 (46%)
1.0
CAPS D (Hyperarousal) <50% decrease
>¼50% decrease
9 (75%)
3 (25%)
10 (77%)
3 (23%)
1.0
<30% decrease
>¼30% decrease
6 (50%)
6 (50%)
8 (62%)
5 (38%)
0.70
CAPS: Clinician Administered PTSD Scale.
Table 3
Change from baseline to endpoint on secondary efﬁcacy measures.
Outcome measure Baseline Change from baseline to endpoint
Ziprasidone
Mean (SD)
Placebo
Mean (SD)
P-value Ziprasidone
Mean (SD)
Placebo
Mean (SD)
P-value
HAM-A 22.5 (7.0) 22.5 (8.5) 1.0 11.8 (12.2) 6.7 (10.8) 0.27
HAM-D 19.0 (4.4) 17.8 (5.4) 0.51 9.8 (8.3) 5.8 (7.6) 0.21
TOP-8 20.0 (5.8) 18.7 (4.4) 0.53 10.1 (8.2) 7.4 (8.0) 0.41
CGI-S 4.9 (0.9) 4.5 (1.0) 0.38 1.9 (1.9) 1.5 (1.7) 0.53
CGI-I 3.5 (0.6) 3.4 (1.2) 0.92 1.2 (1.3) 0.7 (1.5) 0.40
HAM-A: Hamilton Anxiety Scale; HAM-D: Hamilton Rating Scale for Depression; TOP-8: Treatment Outcome PTSD Scale; CGI-S: Clinical Global Impression-Severity; CGI-I:
Clinical Global Impression-Improvement.
Note: As the CGI-I is not obtained at baseline (Visit 1), Visit 2 scores are reported for Baseline.
Endpoint scores on secondary efﬁcacy measures were unavailable for four patients (2 in ziprasidone group and 2 in placebo group). Baseline CGI-S was unavailable for one
patient in the ziprasidone group, and visit 2 CGI-I was unavailable for one patient in the placebo group.
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Seven of the patients randomized in the study discontinued due
to an adverse event, including four (26.7%) in the placebo group and
three (20%) in the ziprasidone group. The most commonly reported
adverse events in our sample were irritability, drowsiness,
insomnia, dizziness, and nausea. There were two serious adverse
events reported during the study, both in patients randomized to
the placebo group. One patient reported chest pain and hyperten-
sion, and a second patient experienced a seizure. Both patients
were discontinued from the trial.
4. Discussion
The primary aim of this study was to assess the efﬁcacy and
tolerability of ziprasidone in patients with chronic PTSD. Contrary
to expectations, we observed no signiﬁcant difference in outcomes
between ziprasidone treatment compared with placebo. These
ﬁndings are in contrast to two previous studies that reported
improvement in PTSD symptoms with ziprasidone treatment
[19,16]. However, this discrepancy may be attributed to differences
in study design. In particular, both previous studies involved in-
patients treated with ziprasidone for approximately a week on
average, while our study focused on outpatients treated with
ziprasidone over a 9-week period. In addition, one of these studies
[19] reported on two patients with chronic combat-related PTSD,
while many of the participants in the current study were recruited
through area women’s trauma groups and treatment centers.
We cannot explain the lack of a treatment effect by insufﬁcient
response to ziprasidone. Total CAPS score changes from baseline
were 28.2 in the ziprasidone treatment group and 22.3 in
placebo-treated patients, and there was no statistically signiﬁcant
difference in response rates between the two groups (25% and 23%
for ziprasidone and placebo, respectively). In addition, no relevant
differences in symptom severity were observed between the
groups at baseline (CAPS mean baseline scores of 79.9 (4.6) and
75.4 (4.6) in the active treatment and placebo-controlled groups,
respectively), making it unlikely that differences in symptomology
contributed to the lack of treatment effect. Placebo response in
clinical trials has been well documented in a variety of psychiatric
patient populations [20e22]. While the double-blind design and
use of standardized measures reduced the potential for bias in our
study, there are other factors (e.g., patient expectancy of improve-
ment, beneﬁt of contact with health care providers, recruitment
strategy) that may have contributed to the high placebo response
rate and reduced our ability to detect a difference between drug
and placebo.
There are a number of limitations of the current study that
should be acknowledged. First, due to the small sample and limitedduration of our study, additional studies in larger samples and over
longer periods will be needed to further evaluate the efﬁcacy of
antipsychotic medications like ziprasidone in treating PTSD. Sec-
ond, our sample was predominantly comprised of women with
PTSD mostly related to sexual or physical assault, and the ﬁndings
from this study may not generalize to all individuals with PTSD
(e.g., military personnel with combat-related PTSD). Finally, ac-
cording to a study by Hamner [23], severity of speciﬁc PTSD
symptoms, as measured by the CAPS and respective symptom
cluster scores, did not predict psychotic features. That is, the psy-
chotic PTSD patients did not have more severe current illness as
measured by these subscales. For example, the “re-experiencing
symptoms” (CAPS cluster B) was not higher in patients with psy-
chotic features. While we did not specﬁcally measure psychotic
symptoms in our study, we believe that future work should include
assessment of the frequency and intensity of psychotic features in
patients using a clinical rating for psychosis, such as the Brief
Psychiatric Rating Scale or the Positive and Negative Symptom
Scale (PANSS).5. Conclusion
In conclusion, we did not ﬁnd any signiﬁcant effect of ziprasi-
done treatment compared to placebo in the reduction of PTSD or
depression symptoms. The high placebo response rate in our study
highlights the importance of better understanding the nature of
placebo response and taking appropriate measures to minimize its
impact in clinical trials.Acknowledgments
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Fig. A.1CAPS total scores by visit for the ziprasidone group. Note: Data were unavailable
for ﬁve patients at visit 7 and three patients at visit 9.1
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Fig. A.2CAPS total scores by visit for the placebo group. Note: Data were unavailable for
six patients at visit 7 and two patients at visit 9.
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